Meanwhile, Lilly also confirmed that it will start running a head-to-head cardiovascular outcomes trial for Trulicity and one of its pipeline diabetes candidates – dual GIP/GLP1 agonist ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback